Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in GSK — GSK plc

CIK 1423053 MIAMI, FL
Back to GSK Full portfolio

Position in GSK

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$7,945,456
+$7,945,456 QoQ
Shares Held
151,573
Ownership
0.008%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#126
of 1,033 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in GSK Over Time

Shares Held

Position Value (USD)

Derivatives in GSK

reported options exposure · as of Jun 30, 2026
CallValue
$20,323,234
CallShares
387,700
PutValue
$17,382,472
PutShares
331,600

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $3,979,998,649 across 21 Drug Manufacturers - General names. GSK ranks #14 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 945,456 $1,134,008,383
2 ABBV
AbbVie Inc.
 3,169,783 $797,644,194
3 GILD
Gilead Sciences, Inc.
 3,480,444 $439,719,294
4 JNJ
Johnson & Johnson
 1,500,832 $381,166,302
5 AMGN
Amgen Inc
 703,984 $254,926,685
6 MRK
Merck & Co., Inc.
 1,933,667 $248,476,209
7 AZN
Astrazeneca PLC
 970,043 $183,939,553
8 PFE
Pfizer Inc
 6,191,186 $149,083,758

All Filings in GSK

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $7,945,456 151,573
2026-06-30 $20,323,234 387,700
2026-06-30 $17,382,472 331,600
2026-03-31 $32,170,251 582,900
2026-03-31 $38,158,366 691,400
2025-12-31 $35,313,704 720,100
2025-12-31 $10,499,414 214,099
2025-12-31 $23,784,400 485,000
2025-09-30 $50,583,520 1,172,000
2025-09-30 $18,377,528 425,800
2025-06-30 $15,859,200 413,000
2025-06-30 $42,274,560 1,100,900
2025-06-30 $4,672,704 121,685
2025-03-31 $17,866,888 461,200
2025-03-31 $32,417,632 836,800
2025-03-31 $62,897,255 1,623,574
2024-12-31 $27,032,326 799,300
2024-12-31 $29,578,972 874,600
2024-12-31 $6,216,589 183,814
2024-09-30 $23,589,354 577,039
2024-09-30 $38,778,768 948,600
2024-09-30 $8,973,160 219,500
2024-06-30 $7,950,250 206,500
2024-06-30 $532,416 13,829
2024-06-30 $27,346,550 710,300
2024-03-31 $26,660,853 621,900
2024-03-31 $9,319,251 217,384
2024-03-31 $8,162,448 190,400
2023-12-31 $4,385,494 118,335
2023-12-31 $10,797,060 291,340
2023-12-31 $20,841,802 562,380
2023-09-30 $19,307,112 532,610
2023-09-30 $17,278,925 476,660
2023-09-30 $21,741,300 599,760
2023-06-30 $15,588,936 437,400
2023-06-30 $980,883 27,522
2023-06-30 $19,295,496 541,400
2023-03-31 $18,161,455 510,440
2023-03-31 $9,879,036 277,657
2023-03-31 $23,491,339 660,240
2022-12-31 $31,616,160 899,720
2022-12-31 $36,396,606 1,035,760
2022-12-31 $32,802,522 933,481
2022-09-30 $72,904,584 2,477,220
2022-09-30 $109,242,481 3,711,943
2022-09-30 $38,794,626 1,318,200
2022-06-30 $46,869,719 1,097,800
2022-06-30 $57,176,488 1,339,209
2022-06-30 $60,258,627 1,411,400
2022-03-31 $50,718,139 1,187,121

Report a Problem

Category
Description
Email (optional, for follow-up)